Trials / Completed
CompletedNCT01454024
Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice
A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,031 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Asia. The aim of of this study is to evaluate the safety of NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of adverse events and technical complaints in patients with type 1 and type 2 diabetes in routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | FlexPen® | Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice |
| DEVICE | NovoPen® 3 | Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2011-10-18
- Last updated
- 2015-06-12
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT01454024. Inclusion in this directory is not an endorsement.